Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Participants who met the following criteria were eligible to participate in this study.~Inclusion Criteria:~* Advanced ovarian epithelial cancer, treated with paracentesis~* Platinum-resistant, and topotecan-resistant and/or liposomal doxorubicin-resistant disease;~* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2.~Exclusion Criteria:~* Pseudomyxoma peritonei or peritoneal mesothelioma;~* Transudative ascites;~* Peritoneovenous or other shunt placed for malignant ascites management;~* Recent (\<6 months) cardiovascular event (pulmonary embolus, myocardial infarction, stroke) or gastrointestinal disease (ulcer, hepatic cirrhosis);~* Known brain metastases;~* Uncontrolled hypertension;~* Recent treatment with chemotherapy, surgery or radiotherapy;~* Prior treatment with VEGF or VEGFR inhibitor.~The above information is not intended to contain all considerations relevant to participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study.
- Aflibercept (Type: EXPERIMENTAL): Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).